Lanifibranor · NATiV3
Inventiva reported the last 72-week visit in September and guides to Q4 2026 topline results. A publication window does not define an immutable settlement deadline. lanifibranor — phase 3 study in NASH - Nonalcoholic Steatohepatitis. NCT04849728 lists Resolution of NASH and improvement of fibrosis as a primary outcome (Part A: Date of randomisation until the date of biopsy at Week 72). Registry status: active not recruiting.
What matters
Track what the company has actually announced, the study or asset involved, and the evidence needed to confirm the milestone.
- Specify the exact future analysis/cohort and verify that it remains unpublished before creating any tradeable question.
- Registry design and recruitment status are not evidence of efficacy or regulatory approval.
- Primary completion is not a guaranteed topline publication or regulatory decision date.
- Registry primary completion: 2027-09-30 (estimated); verify independently before using it as a catalyst date.
- An active study record does not establish that its primary outcome is still unannounced. Review sponsor disclosures before promotion to a future catalyst.
- The registry lists 2 primary outcome measures. A market must explicitly specify which endpoint or conjunction resolves YES; this card highlights one measure only.
Primary evidence
Sponsor expectation: Q4 2026 — exact day unconfirmed
Potential outcome market
Will lanifibranor meet the prespecified primary endpoint in NCT04849728 by a listing deadline still to be specified?
This event is research, not a listed market. A market needs a precise question, resolution rules and liquidity before trading opens.